The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Lewis Karen since 2023.
This trader's CIK number is 1814304.
At the time of last reporting, Lewis Karen was the Chief People Officer of Apellis Pharmaceuticals, Inc.. (stock ticker symbol APLS).
Also see all insider trading activities at Apellis Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | APLS | 0 | $0 | 4,955 | $147,092 | 0 | $0 |
| 2024 | APLS | 0 | $0 | 10,550 | $682,178 | 0 | $0 |
| 2023 | APLS | 0 | $0 | 16,987 | $1,357,498 | 15,000 | $511,650 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-29 | APLS | Sale | 364 | 29.52 | 10,746 |
| 2025-01-22 | APLS | Sale | 1,751 | 30.43 | 53,275 |
| 2025-01-17 | APLS | Sale | 1,241 | 29.96 | 37,177 |
| 2025-01-13 | APLS | Sale | 1,599 | 28.70 | 45,894 |
| 2024-01-29 | APLS | Sale | 367 | 64.14 | 23,538 |
| 2024-01-30 | APLS | Sale | 883 | 65.53 | 57,862 |
| 2024-01-23 | APLS | Sale | 4,286 | 63.69 | 272,975 |
| 2024-01-22 | APLS | Sale | 1,738 | 65.00 | 112,963 |
| 2024-01-17 | APLS | Sale | 3,276 | 65.58 | 214,840 |
| 2023-06-01 | APLS | Option Ex | 5,000 | 34.11 | 170,550 |
| 2023-06-01 | APLS | Sale | 5,000 | 86.00 | 430,000 |
| 2023-06-01 | APLS | Option Ex | 5,000 | 34.11 | 170,550 |
| 2023-06-01 | APLS | Sale | 5,000 | 86.00 | 430,000 |
| 2023-04-03 | APLS | Option Ex | 5,000 | 34.11 | 170,550 |
| 2023-04-03 | APLS | Sale | 5,000 | 75.00 | 375,000 |
| 2023-02-23 | APLS | Sale | 1,104 | 68.76 | 75,911 |
| 2023-01-30 | APLS | Sale | 883 | 52.76 | 46,587 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lewis Karen (Chief People Officer of Apellis Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.